Relationship of healthcare costs and disease progression in patients with HER2+ breast cancer.

Abstract

e13013 Background: Reducing disease recurrence with better treatments in the adjuvant setting may alleviate the economic burden associated with metastatic disease in HER2 positive breast cancer (BC). Analyses were performed to complement existing literature on the cost of metastatic HER2+ breast cancer given the introduction of new treatment options since 2012. Methods: We performed a retrospective cohort study using Truven Marketscan 2011-2016 commercial and Medicare administrative claims data. Metastatic BC patients were followed for up to three years and healthcare costs (hospital stays, prescription costs, outpatient services) were analyzed. An additional matched cohort analysis was performed for recurrent patients, selecting adjuvant treated patients who did not progress with similar age, year of initial anti-HER2 treatment, anti-HER2 treatment duration and follow-up duration. Results: Three year costs following a diagnosis of metastatic BC cancer were $470,240. The matched cohort analysis showed patients with metastatic BC incurred costs greater than $240,000 vs. less than $20,000 for a cohort of adjuvant treated patients who did not progress in the first year post-index date. Average Healthcare Costs After Metastasis in HER2+ Breast Cancer Conclusions: Total healthcare costs in the first year after metastatic diagnosis was high in HER2+ breast cancer patients. Relative to healthcare costs in patients treated in the early BC setting who did not progress, metastatic BC costs were over $240,000 vs less than $20,000 for a comparable cohort of patients. Reducing recurrences with better treatment in the adjuvant setting may be important in alleviating the economic burden associated with HER2 positive metastatic breast cancer Sample Costs in the 1st year after metastasis Mean (SE) Costs in 2 years after metastasis Mean (SE) Costs in 3 years after metastasis Mean (SE) Pts with at least 1yr follow-up (N = 1,799) 267,485 (3,737) Pts with at least 2yr follow-up (N = 910) 257,316 (5,257) 382,115 (8,704) Pts with at least 3yr follow-up (N = 391) 248,759 (7,904) 366,811 (13,383) 470,240 (18,672)